{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:12:26Z","timestamp":1779149546718,"version":"3.51.4"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institutes of Health (NIH) Director\u2019s Pioneer Award","award":["DP1OD006779"],"award-info":[{"award-number":["DP1OD006779"]}]},{"name":"NIH Clinical and Translational Sciences (NCATS) Award","award":["UL1TR001412"],"award-info":[{"award-number":["UL1TR001412"]}]},{"name":"NIH National Library of Medicine (NLM) T15 Award","award":["T15LM012495"],"award-info":[{"award-number":["T15LM012495"]}]},{"name":"NIH NLM R25 Award","award":["R25LM014213"],"award-info":[{"award-number":["R25LM014213"]}]},{"name":"NIH NCATS ASPIRE Design Challenge Award"},{"name":"NIH NCATS ASPIRE Reduction-to-Practice Award"},{"name":"National Institute of Standards of Technology (NIST) Award","award":["60NANB22D168"],"award-info":[{"award-number":["60NANB22D168"]}]},{"name":"NIDA Mentored Research Scientist Development Award","award":["K01DA056690"],"award-info":[{"award-number":["K01DA056690"]}]},{"name":"startup funds from the Department of Biomedical Informatics at the University at Buffalo"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioma is a highly malignant brain tumor with limited treatment options. We employed the Computational Analysis of Novel Drug Opportunities (CANDO) platform for multiscale therapeutic discovery to predict new glioma therapies. We began by computing interaction scores between extensive libraries of drugs\/compounds and proteins to generate \u201cinteraction signatures\u201d that model compound behavior on a proteomic scale. Compounds with signatures most similar to those of drugs approved for a given indication were considered potential treatments. These compounds were further ranked by degree of consensus in corresponding similarity lists. We benchmarked performance by measuring the recovery of approved drugs in these similarity and consensus lists at various cutoffs, using multiple metrics and comparing results to random controls and performance across all indications. Compounds ranked highly by consensus but not previously associated with the indication of interest were considered new predictions. Our benchmarking results showed that CANDO improved accuracy in identifying glioma-associated drugs across all cutoffs compared to random controls. Our predictions, supported by literature-based analysis, identified 24 potential glioma treatments, including approved drugs like vitamin D, taxanes, vinca alkaloids, topoisomerase inhibitors, and folic acid, as well as investigational compounds such as ginsenosides, chrysin, resiniferatoxin, and cryptotanshinone. Further functional annotation-based analysis of the top targets with the strongest interactions to these predictions identified Vitamin D3 receptor, thyroid hormone receptor, acetylcholinesterase, cyclin-dependent kinase 2, tubulin alpha chain, dihydrofolate reductase, and thymidylate synthase. These findings indicate that CANDO\u2019s multitarget, multiscale framework is effective in identifying glioma drug candidates thereby informing new strategies for improving treatment.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Scientific contribution<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>(1) We present a robust, multiscale drug discovery framework that accurately recovers known glioma therapies and uncovers 24 novel candidates with strong literature and mechanistic support. (2) By modeling compound behavior across the proteome, our method pinpoints key targets\u2013including VDR, CDK2, and DHFR\u2013implicated in glioma biology. (3) This work positions CANDO as a powerful tool for rational repurposing and discovery of urgently needed treatments for aggressive brain tumors.<\/jats:p>","DOI":"10.1186\/s13321-026-01191-9","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T08:04:41Z","timestamp":1775981081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform"],"prefix":"10.1186","volume":"18","author":[{"given":"Sumei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Mangione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Van Norden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Elefteriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zackary","family":"Falls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Samudrala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"1191_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10143-016-0709-8","volume":"40","author":"NAO Bush","year":"2017","unstructured":"Bush NAO, Chang SM, Berger MS (2017) Current and future strategies for treatment of glioma. Neurosurg Rev 40:1\u201314","journal-title":"Neurosurg Rev"},{"key":"1191_CR2","first-page":"50","volume-title":"Seminars in cancer biology","author":"O Gusyatiner","year":"2018","unstructured":"Gusyatiner O, Hegi ME, Rosenquist R, Plass C, Badosa ME (2018) Glioma epigenetics: from subclassification to novel treatment options. In: Rosenquist R, Plass C, Badosa ME (eds) Seminars in cancer biology. Elsevier, Amsterdam, pp 50\u201358"},{"key":"1191_CR3","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/IJN.S243223","volume":"15","author":"J Li","year":"2020","unstructured":"Li J et al (2020) Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J Nanomed 15:2563\u20132582","journal-title":"Int J Nanomed"},{"key":"1191_CR4","doi-asserted-by":"publisher","first-page":"52319","DOI":"10.1021\/acsami.0c12971","volume":"12","author":"H Xu","year":"2020","unstructured":"Xu H et al (2020) Hypoxia-responsive lipid-polymer nanoparticle-combined imaging-guided surgery and multitherapy strategies for glioma. ACS Appl Mate Interfaces 12:52319\u201352328","journal-title":"ACS Appl Mate Interfaces"},{"key":"1191_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-030-30651-9_5","volume-title":"Glioma signaling","author":"E Braganhol","year":"2020","unstructured":"Braganhol E, Wink MR, Lenz G, Battastini AMO (2020) Purinergic signaling in glioma progression. In: Bara\u0144ska J (ed) Glioma signaling. Springer, Cham, pp 87\u2013108"},{"key":"1191_CR6","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.2147\/IJN.S270208","volume":"15","author":"L Lu","year":"2020","unstructured":"Lu L et al (2020) A dual receptor targeting-and bbb penetrating-peptide functionalized polyethyleneimine nanocomplex for secretory endostatin gene delivery to malignant glioma. Int J Nanomed 15:8875\u20138892","journal-title":"Int J Nanomed"},{"key":"1191_CR7","doi-asserted-by":"publisher","first-page":"e27351","DOI":"10.1002\/pbc.27351","volume":"65","author":"L Rosca","year":"2018","unstructured":"Rosca L, Robert-Boire V, Delisle J-F, Samson Y, Perreault S (2018) Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas. Pediatr Blood Cancer 65:e27351","journal-title":"Pediatr Blood Cancer"},{"key":"1191_CR8","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.2147\/IJN.S263956","volume":"15","author":"A Thakur","year":"2020","unstructured":"Thakur A et al (2020) Inhibition of glioma cells\u2019 proliferation by doxorubicin-loaded exosomes via microfluidics. Int J Nanomed 15:8331\u20138343","journal-title":"Int J Nanomed"},{"key":"1191_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbrc.2020.10.076","volume":"534","author":"J Zhu","year":"2021","unstructured":"Zhu J et al (2021) Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming bbb. Biochem Biophys Res Commun 534:902\u2013907","journal-title":"Biochem Biophys Res Commun"},{"key":"1191_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jconrel.2020.08.010","volume":"327","author":"B Han","year":"2020","unstructured":"Han B et al (2020) The influx\/efflux mechanisms of d-peptide ligand of nachrs across the blood-brain barrier and its therapeutic value in treating glioma. J Control Release 327:384\u2013396","journal-title":"J Control Release"},{"key":"1191_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/nos273","volume":"15","author":"M Weller","year":"2013","unstructured":"Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol 15:4\u201327","journal-title":"Neuro Oncol"},{"key":"1191_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3\u201314","journal-title":"NeuroRx"},{"key":"1191_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for cns drug delivery. Nat Rev Drug Discov 15:275\u2013292","journal-title":"Nat Rev Drug Discov"},{"key":"1191_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/scipharm87010006","volume":"87","author":"LA Bors","year":"2019","unstructured":"Bors LA, Erd\u0151 F (2019) Overcoming the blood-brain barrier. challenges and tricks for cns drug delivery. Sci Pharm 87:6","journal-title":"Sci Pharm"},{"key":"1191_CR15","doi-asserted-by":"publisher","first-page":"e225012","DOI":"10.1001\/jamahealthforum.2022.5012","volume":"4","author":"L Clemans-Cope","year":"2023","unstructured":"Clemans-Cope L, Epstein M, Banthin J, Kesselheim AS, Hwang TJ, Ayanian JZ et al (2023) Estimates of medicaid and non-medicaid net prices of top-selling brand-name drugs incorporating best price rebates, 2015 to 2019. JAMA Health Forum 4:e225012","journal-title":"JAMA Health Forum"},{"key":"1191_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-0838-4","volume":"14","author":"A Schuhmacher","year":"2016","unstructured":"Schuhmacher A, Gassmann O, Hinder M (2016) Changing r&d models in research-based pharmaceutical companies. J Transl Med 14:1\u201311","journal-title":"J Transl Med"},{"key":"1191_CR17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/nrd941","volume":"1","author":"J Bajorath","year":"2002","unstructured":"Bajorath J (2002) Integration of virtual and high-throughput screening. Nat Rev Drug Discov 1:882\u2013894","journal-title":"Nat Rev Drug Discov"},{"key":"1191_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.msec.2018.12.038","volume":"97","author":"A Dhasmana","year":"2019","unstructured":"Dhasmana A, Singh L, Roy P, Mishra NC (2019) Silk fibroin protein modified acellular dermal matrix for tissue repairing and regeneration. Mater Sci Eng, C 97:313\u2013324","journal-title":"Mater Sci Eng, C"},{"key":"1191_CR19","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1039\/D0SC06805E","volume":"12","author":"DE Graff","year":"2021","unstructured":"Graff DE, Shakhnovich EI, Coley CW (2021) Accelerating high-throughput virtual screening through molecular pool-based active learning. Chem Sci 12:7866\u20137881","journal-title":"Chem Sci"},{"key":"1191_CR20","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1021\/acs.jcim.9b00387","volume":"59","author":"J Lim","year":"2019","unstructured":"Lim J et al (2019) Predicting drug-target interaction using a novel graph neural network with 3d structure-embedded graph representation. J Chem Inf Model 59:3981\u20133988","journal-title":"J Chem Inf Model"},{"key":"1191_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1582-4934.2008.00665.x","volume":"13","author":"V Zoete","year":"2009","unstructured":"Zoete V, Grosdidier A, Michielin O (2009) Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 13:238\u2013248","journal-title":"J Cell Mol Med"},{"key":"1191_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-020-00471-2","volume":"12","author":"EJ Ha","year":"2020","unstructured":"Ha EJ, Lwin CT, Durrant JD (2020) Liggrep: a tool for filtering docked poses to improve virtual-screening hit rates. J Cheminform 12:1\u201312","journal-title":"J Cheminform"},{"key":"1191_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1021\/ci700376c","volume":"48","author":"HS Lee","year":"2008","unstructured":"Lee HS et al (2008) Optimization of high throughput virtual screening by combining shape-matching and docking methods. J Chem Inf Model 48:489\u2013497","journal-title":"J Chem Inf Model"},{"key":"1191_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/ci8004176","volume":"49","author":"CR Corbeil","year":"2009","unstructured":"Corbeil CR, Moitessier N (2009) Docking ligands into flexible and solvated macromolecules. 3. impact of input ligand conformation, protein flexibility, and water molecules on the accuracy of docking programs. J Chem Inf Model 49:997\u20131009","journal-title":"J Chem Inf Model"},{"key":"1191_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/ci200598m","volume":"52","author":"M Feher","year":"2012","unstructured":"Feher M, Williams CI (2012) Numerical errors and chaotic behavior in docking simulations. J Chem Inf Model 52:724\u2013738","journal-title":"J Chem Inf Model"},{"key":"1191_CR26","doi-asserted-by":"publisher","first-page":"509129","DOI":"10.3389\/fphar.2020.00269","volume":"11","author":"R Shayakhmetov","year":"2020","unstructured":"Shayakhmetov R et al (2020) Molecular generation for desired transcriptome changes with adversarial autoencoders. Front Pharmacol 11:509129","journal-title":"Front Pharmacol"},{"key":"1191_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12539-011-0051-8","volume":"3","author":"L Yang","year":"2011","unstructured":"Yang L et al (2011) Chemical-protein interactome and its application in off-target identification. Interdiscip Sci Comput Life Sci 3:22\u201330","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"1191_CR28","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2174\/138620711795767811","volume":"14","author":"T Liu","year":"2011","unstructured":"Liu T, Tang WG, Capriotti E (2011) Comparative modeling: the state of the art and protein drug target structure prediction. Comb Chem High Throughput Screen 14:532\u2013547","journal-title":"Comb Chem High Throughput Screen"},{"key":"1191_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-7-S5-S6","volume":"7","author":"C Wu","year":"2013","unstructured":"Wu C, Gudivada RC, Aronow BJ, Jegga AG (2013) Computational drug repositioning through heterogeneous network clustering. BMC Syst Biol 7:1\u20139","journal-title":"BMC Syst Biol"},{"key":"1191_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ph11020057","volume":"11","author":"JK Yella","year":"2018","unstructured":"Yella JK, Yaddanapudi S, Wang Y, Jegga AG (2018) Changing trends in computational drug repositioning. Pharmaceuticals 11:57","journal-title":"Pharmaceuticals"},{"key":"1191_CR31","first-page":"297","volume":"13","author":"AD Boran","year":"2010","unstructured":"Boran AD, Iyengar R (2010) Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Dev 13:297","journal-title":"Curr Opin Drug Discov Dev"},{"key":"1191_CR32","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1093\/bioinformatics\/bty133","volume":"34","author":"A Peyvandipour","year":"2018","unstructured":"Peyvandipour A, Saberian N, Shafi A, Donato M, Draghici S (2018) A novel computational approach for drug repurposing using systems biology. Bioinformatics 34:2817\u20132825","journal-title":"Bioinformatics"},{"key":"1191_CR33","doi-asserted-by":"publisher","first-page":"434647","DOI":"10.3389\/fgene.2019.00159","volume":"10","author":"A Shafi","year":"2019","unstructured":"Shafi A, Nguyen T, Peyvandipour A, Nguyen H, Draghici S (2019) A multi-cohort and multi-omics meta-analysis framework to identify network-based gene signatures. Front Genet 10:434647","journal-title":"Front Genet"},{"key":"1191_CR34","first-page":"523","volume-title":"New look to phytomedicine","author":"A Dhasmana","year":"2019","unstructured":"Dhasmana A, Raza S, Jahan R, Lohani M, Arif JM (2019) High-throughput virtual screening (htvs) of natural compounds and exploration of their biomolecular mechanisms: an in silico approach. In: Khan MSA, Ahmad I, Chattopadhyay D (eds) New look to phytomedicine. Elsevier, Amsterdam, pp 523\u2013548"},{"key":"1191_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2009-10-9-238","volume":"10","author":"NP Tatonetti","year":"2009","unstructured":"Tatonetti NP, Liu T, Altman RB (2009) Predicting drug side-effects by chemical systems biology. Genome Biol 10:1\u20134","journal-title":"Genome Biol"},{"key":"1191_CR36","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1021\/acs.jcim.5b00030","volume":"55","author":"T Liu","year":"2015","unstructured":"Liu T, Altman RB (2015) Relating essential proteins to drug side-effects using canonical component analysis: a structure-based approach. J Chem Inf Model 55:1483\u20131494","journal-title":"J Chem Inf Model"},{"key":"1191_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4939-8955-3_5","volume-title":"Computational methods for drug repurposing","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yella J, Jegga AG (2019) Transcriptomic data mining and repurposing for computational drug discovery. In: Vanhaelen Q (ed) Computational methods for drug repurposing. Humana Press, New York, pp 73\u201395"},{"key":"1191_CR38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.drudis.2014.06.018","volume":"19","author":"M Minie","year":"2014","unstructured":"Minie M et al (2014) Cando and the infinite drug discovery frontier. Drug Discov Today 19:1353\u20131363","journal-title":"Drug Discov Today"},{"key":"1191_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2174\/1389557515666150219145148","volume":"15","author":"G Sethi","year":"2015","unstructured":"Sethi G, Chopra G, Samudrala R (2015) Multiscale modelling of relationships between protein classes and drug behavior across all diseases using the Cando platform. Mini Rev Med Chem 15:705\u2013717","journal-title":"Mini Rev Med Chem"},{"key":"1191_CR40","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.2174\/1381612822666160325121943","volume":"22","author":"G Chopra","year":"2016","unstructured":"Chopra G, Samudrala R (2016) Exploring polypharmacology in drug discovery and repurposing using the Cando platform. Curr Pharm Des 22:3109\u20133123","journal-title":"Curr Pharm Des"},{"key":"1191_CR41","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/molecules21121537","volume":"21","author":"G Chopra","year":"2016","unstructured":"Chopra G, Kaushik S, Elkin PL, Samudrala R (2016) Combating ebola with repurposed therapeutics using the Cando platform. Molecules 21:1537","journal-title":"Molecules"},{"key":"1191_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/molecules24010167","volume":"24","author":"W Mangione","year":"2019","unstructured":"Mangione W, Samudrala R (2019) Identifying protein features responsible for improved drug repurposing accuracies using the Cando platform: implications for drug design. Molecules 24:167","journal-title":"Molecules"},{"key":"1191_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-019-4356-3","volume":"12","author":"Z Falls","year":"2019","unstructured":"Falls Z, Mangione W, Schuler J, Samudrala R (2019) Exploration of interaction scoring criteria in the Cando platform. BMC Res Notes 12:1\u20136","journal-title":"BMC Res Notes"},{"key":"1191_CR44","doi-asserted-by":"publisher","first-page":"17393","DOI":"10.1021\/acsomega.9b02160","volume":"4","author":"J Schuler","year":"2019","unstructured":"Schuler J, Samudrala R (2019) Fingerprinting Cando: increased accuracy with structure-and ligand-based shotgun drug repurposing. ACS Omega 4:17393\u201317403","journal-title":"ACS Omega"},{"key":"1191_CR45","doi-asserted-by":"publisher","first-page":"13155","DOI":"10.1038\/s41598-019-49515-0","volume":"9","author":"J Fine","year":"2019","unstructured":"Fine J, Lackner R, Samudrala R, Chopra G (2019) Computational chemoproteomics to understand the role of selected psychoactives in treating mental health indications. Sci Rep 9:13155","journal-title":"Sci Rep"},{"key":"1191_CR46","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1021\/acs.jcim.0c00110","volume":"60","author":"W Mangione","year":"2020","unstructured":"Mangione W, Falls Z, Chopra G, Samudrala R (2020) CANDO. py: open source software for predictive bioanalytics of large scale drug-protein-disease data. J Chem Inf Model 60:4131\u20134136","journal-title":"J Chem Inf Model"},{"key":"1191_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.drudis.2020.05.002","volume":"25","author":"W Mangione","year":"2020","unstructured":"Mangione W, Falls Z, Melendy T, Chopra G, Samudrala R (2020) Shotgun drug repurposing biotechnology to tackle epidemics and pandemics. Drug Discov Today 25:1126","journal-title":"Drug Discov Today"},{"key":"1191_CR48","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3390\/molecules26092581","volume":"26","author":"ML Hudson","year":"2021","unstructured":"Hudson ML, Samudrala R (2021) Multiscale virtual screening optimization for shotgun drug repurposing using the CANDO platform. Molecules 26:2581","journal-title":"Molecules"},{"key":"1191_CR49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/ph14121277","volume":"14","author":"B Overhoff","year":"2021","unstructured":"Overhoff B, Falls Z, Mangione W, Samudrala R (2021) A deep-learning proteomic-scale approach for drug design. Pharmaceuticals 14:1277","journal-title":"Pharmaceuticals"},{"key":"1191_CR50","doi-asserted-by":"publisher","first-page":"970494","DOI":"10.3389\/fphar.2022.970494","volume":"13","author":"W Mangione","year":"2022","unstructured":"Mangione W, Falls Z, Samudrala R (2022) Optimal covid-19 therapeutic candidate discovery using the CANDO platform. Front Pharmacol 13:970494","journal-title":"Front Pharmacol"},{"key":"1191_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.drudis.2021.08.002","volume":"27","author":"J Schuler","year":"2022","unstructured":"Schuler J et al (2022) Evaluating the performance of drug-repurposing technologies. Drug Discov Today 27:49\u201364","journal-title":"Drug Discov Today"},{"key":"1191_CR52","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/ijms24020997","volume":"24","author":"L Bruggemann","year":"2023","unstructured":"Bruggemann L et al (2023) Multiscale analysis and validation of effective drug combinations targeting driver kras mutations in non-small cell lung cancer. Int J Mol Sci 24:997","journal-title":"Int J Mol Sci"},{"key":"1191_CR53","doi-asserted-by":"publisher","first-page":"1113007","DOI":"10.3389\/fphar.2023.1113007","volume":"14","author":"W Mangione","year":"2023","unstructured":"Mangione W, Falls Z, Samudrala R (2023) Effective holistic characterization of small molecule effects using heterogeneous biological networks. Front Pharmacol 14:1113007","journal-title":"Front Pharmacol"},{"key":"1191_CR54","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/jama.294.12.1490","volume":"294","author":"E Jenwitheesuk","year":"2005","unstructured":"Jenwitheesuk E, Samudrala R (2005) Identification of potential multitarget antimalarial drugs. JAMA 294:1487\u20131491","journal-title":"JAMA"},{"key":"1191_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tips.2007.11.007","volume":"29","author":"E Jenwitheesuk","year":"2008","unstructured":"Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R (2008) Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci 29:62\u201371","journal-title":"Trends Pharmacol Sci"},{"key":"1191_CR56","doi-asserted-by":"publisher","first-page":"e721","DOI":"10.1371\/journal.pntd.0000721","volume":"4","author":"JM Costin","year":"2010","unstructured":"Costin JM et al (2010) Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl Trop Dis 4:e721","journal-title":"PLoS Negl Trop Dis"},{"key":"1191_CR57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.antiviral.2010.11.008","volume":"89","author":"CO Nicholson","year":"2011","unstructured":"Nicholson CO et al (2011) Viral entry inhibitors block dengue antibody-dependent enhancement in vitro. Antivir Res 89:71\u201374","journal-title":"Antivir Res"},{"key":"1191_CR58","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1021\/acs.jcim.9b00686","volume":"60","author":"J Fine","year":"2020","unstructured":"Fine J, Konc J, Samudrala R, Chopra G (2020) Candock: chemical atomic network-based hierarchical flexible docking algorithm using generalized statistical potentials. J Chem Inf Model 60:1509\u20131527","journal-title":"J Chem Inf Model"},{"key":"1191_CR59","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.chembiol.2021.02.007","volume":"28","author":"R Chatrikhi","year":"2021","unstructured":"Chatrikhi R et al (2021) A synthetic small molecule stalls pre-mrna splicing by promoting an early-stage u2af2-rna complex. Cell Chem Biol 28:1145\u20131157","journal-title":"Cell Chem Biol"},{"key":"1191_CR60","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1038\/s41467-021-23985-1","volume":"12","author":"L Palanikumar","year":"2021","unstructured":"Palanikumar L et al (2021) Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun 12:3962","journal-title":"Nat Commun"},{"key":"1191_CR61","unstructured":"Michael SF et\u00a0al (2013) Optimized dengue virus entry inhibitory peptide (dn81) . US Patent 8,541,377"},{"key":"1191_CR62","unstructured":"Michael S et\u00a0al (2014) Optimized dengue virus entry inhibitory peptide (1oan1)"},{"key":"1191_CR63","doi-asserted-by":"publisher","first-page":"775513","DOI":"10.3389\/fchem.2021.775513","volume":"9","author":"Z Falls","year":"2022","unstructured":"Falls Z, Fine J, Chopra G, Samudrala R (2022) Accurate prediction of inhibitor binding to hiv-1 protease using candock. Front Chem 9:775513","journal-title":"Front Chem"},{"key":"1191_CR64","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/ph15050566","volume":"15","author":"MJ Mammen","year":"2022","unstructured":"Mammen MJ et al (2022) Proteomic network analysis of bronchoalveolar lavage fluid in ex-smokers to discover implicated protein targets and novel drug treatments for chronic obstructive pulmonary disease. Pharmaceuticals 15:566","journal-title":"Pharmaceuticals"},{"key":"1191_CR65","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074\u2013D1082","journal-title":"Nucleic Acids Res"},{"key":"1191_CR66","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J et al (2021) Highly accurate protein structure prediction with alphafold. Nature 596:583\u2013589","journal-title":"Nature"},{"key":"1191_CR67","doi-asserted-by":"publisher","first-page":"D1138","DOI":"10.1093\/nar\/gkaa891","volume":"49","author":"AP Davis","year":"2021","unstructured":"Davis AP et al (2021) Comparative toxicogenomics database (ctd): update 2021. Nucleic Acids Res 49:D1138\u2013D1143","journal-title":"Nucleic Acids Res"},{"key":"1191_CR68","first-page":"265","volume":"88","author":"CE Lipscomb","year":"2000","unstructured":"Lipscomb CE (2000) Medical subject headings (mesh). Bull Med Libr Assoc 88:265","journal-title":"Bull Med Libr Assoc"},{"key":"1191_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nmeth.3213","volume":"12","author":"J Yang","year":"2015","unstructured":"Yang J et al (2015) The i-tasser suite: protein structure and function prediction. Nat Methods 12:7\u20138","journal-title":"Nat Methods"},{"key":"1191_CR70","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/bioinformatics\/btt447","volume":"29","author":"J Yang","year":"2013","unstructured":"Yang J, Roy A, Zhang Y (2013) Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics 29:2588\u20132595","journal-title":"Bioinformatics"},{"key":"1191_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1758-2946-5-26","volume":"5","author":"S Riniker","year":"2013","unstructured":"Riniker S, Landrum GA (2013) Open-source platform to benchmark fingerprints for ligand-based virtual screening. J Cheminform 5:26","journal-title":"J Cheminform"},{"key":"1191_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1590\/S1415-47571999000300024","volume":"22","author":"JM Duarte","year":"1999","unstructured":"Duarte JM, Santos JBD, Melo LC (1999) Comparison of similarity coefficients based on rapd markers in the common bean. Genet Mol Biol 22:427\u2013432","journal-title":"Genet Mol Biol"},{"key":"1191_CR73","doi-asserted-by":"publisher","first-page":"D1257","DOI":"10.1093\/nar\/gkac833","volume":"51","author":"AP Davis","year":"2023","unstructured":"Davis AP et al (2023) Comparative toxicogenomics database (ctd): update 2023. Nucleic Acids Res 51:D1257\u2013D1262","journal-title":"Nucleic Acids Res"},{"key":"1191_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.brainres.2007.06.044","volume":"1202","author":"AC Felch","year":"2008","unstructured":"Felch AC, Granger RH (2008) The hypergeometric connectivity hypothesis: divergent performance of brain circuits with different synaptic connectivity distributions. Brain Res 1202:3\u201313","journal-title":"Brain Res"},{"key":"1191_CR75","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1145\/582415.582418","volume":"20","author":"K J\u00e4rvelin","year":"2002","unstructured":"J\u00e4rvelin K, Kek\u00e4l\u00e4inen J (2002) Cumulated gain-based evaluation of ir techniques. ACM Trans Inf Syst (TOIS) 20:422\u2013446","journal-title":"ACM Trans Inf Syst (TOIS)"},{"key":"1191_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/978-3-642-24583-1_2","volume-title":"International symposium on string processing and information retrieval","author":"G Dupret","year":"2011","unstructured":"Dupret G, Grossi R, Sebastiani F, Silvestri F (2011) Discounted cumulative gain and user decision models. In: Grossi R, Sebastiani F, Silvestri F (eds) International symposium on string processing and information retrieval. Springer, Berlin, pp 2\u201313"},{"key":"1191_CR77","doi-asserted-by":"publisher","first-page":"17393","DOI":"10.1021\/acsomega.9b02160","volume":"4","author":"J Schuler","year":"2019","unstructured":"Schuler J, Samudrala R (2019) Fingerprinting CANDO: increased accuracy with structure- and ligand-based shotgun drug repurposing. ACS Omega 4:17393\u201317403","journal-title":"ACS Omega"},{"key":"1191_CR78","first-page":"283","volume":"10","author":"S Garattini","year":"1997","unstructured":"Garattini S (1997) Are me-too drugs justified? J Nephrol 10:283\u2013294","journal-title":"J Nephrol"},{"key":"1191_CR79","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s10729-013-9225-3","volume":"16","author":"S R\u00e9gnier","year":"2013","unstructured":"R\u00e9gnier S (2013) What is the value of \u201cme-too\u201d drugs? Health Care Manag Sci 16:300\u2013313","journal-title":"Health Care Manag Sci"},{"key":"1191_CR80","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1111\/bcp.14327","volume":"86","author":"JK Aronson","year":"2020","unstructured":"Aronson JK, Green AR (2020) Me-too pharmaceutical products: history, definitions, examples, and relevance to drug shortages and essential medicines lists. British J Clin Pharmacol 86:2114\u20132122","journal-title":"British J Clin Pharmacol"},{"key":"1191_CR81","doi-asserted-by":"publisher","first-page":"D506","DOI":"10.1093\/nar\/gky1049","volume":"47","author":"Consortium U","year":"2019","unstructured":"Consortium U (2019) Uniprot: a worldwide hub of protein knowledge. Nucleic Acids Res 47:D506\u2013D515","journal-title":"Nucleic Acids Res"},{"key":"1191_CR82","doi-asserted-by":"crossref","first-page":"D18","DOI":"10.1093\/nar\/gkv905","volume":"44","author":"G Stelzer","year":"2016","unstructured":"Stelzer G et al (2016) Genecards: the human gene database. Nucleic Acids Res 44:D18\u2013D24","journal-title":"Nucleic Acids Res"},{"key":"1191_CR83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1469-8137.1912.tb05611.x","volume":"11","author":"P Jaccard","year":"1912","unstructured":"Jaccard P (1912) The distribution of the flora in the alpine zone. 1. New Phytol 11:37\u201350","journal-title":"New Phytol"},{"key":"1191_CR84","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s12859-019-3118-5","volume":"20","author":"NC Chung","year":"2019","unstructured":"Chung NC, Miasojedow B, Startek M, Gambin A (2019) Jaccard\/Tanimoto similarity test and estimation methods for biological presence-absence data. BMC Bioinform 20:644","journal-title":"BMC Bioinform"},{"key":"1191_CR85","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2174\/156800910793357970","volume":"10","author":"H-W Lo","year":"2010","unstructured":"Lo H-W (2010) Targeting ras-raf-erk and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 10:840\u2013848","journal-title":"Curr Cancer Drug Targets"},{"key":"1191_CR86","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1586\/14737140.4.1.105","volume":"4","author":"HB Newton","year":"2004","unstructured":"Newton HB (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: Pi3k\/akt\/pten, mtor, shh\/ptch and angiogenesis. Expert Rev Anticancer Ther 4:105\u2013128","journal-title":"Expert Rev Anticancer Ther"},{"key":"1191_CR87","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/neuonc\/nos302","volume":"15","author":"OD Stechishin","year":"2013","unstructured":"Stechishin OD et al (2013) On-target jak2\/stat3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro Oncol 15:198\u2013207","journal-title":"Neuro Oncol"},{"key":"1191_CR88","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/neuonc\/nos139","volume":"14","author":"TA Doucette","year":"2012","unstructured":"Doucette TA et al (2012) Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14:1136\u20131145","journal-title":"Neuro Oncol"},{"key":"1191_CR89","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/2211-5463.13679","volume":"13","author":"R Yuan","year":"2023","unstructured":"Yuan R et al (2023) Vitamin d3 suppresses the cholesterol homeostasis pathway in patient-derived glioma cell lines. FEBS Open Bio 13:1789\u20131806","journal-title":"FEBS Open Bio"},{"key":"1191_CR90","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1158\/1078-0432.CCR-04-1968","volume":"11","author":"B Diesel","year":"2005","unstructured":"Diesel B et al (2005) Vitamin d3 metabolism in human glioblastoma multiforme: functionality of cyp27b1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clin Cancer Res 11:5370\u20135380","journal-title":"Clin Cancer Res"},{"key":"1191_CR91","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41374-021-00673-8","volume":"102","author":"CS-C Lo","year":"2022","unstructured":"Lo CS-C, Kiang KM-Y, Leung GK-K (2022) Anti-tumor effects of vitamin d in glioblastoma: mechanism and therapeutic implications. Lab Invest 102:118\u2013125","journal-title":"Lab Invest"},{"key":"1191_CR92","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1159\/000495274","volume":"51","author":"H-J Liu","year":"2018","unstructured":"Liu H-J et al (2018) Sulforaphane-n-acetyl-cysteine induces autophagy through activation of erk1\/2 in u87mg and u373mg cells. Cell Physiol Biochem 51:528\u2013542","journal-title":"Cell Physiol Biochem"},{"key":"1191_CR93","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12885-022-09595-0","volume":"22","author":"X Hu","year":"2022","unstructured":"Hu X et al (2022) The oncogenic role of tubulin alpha-1c chain in human tumours. BMC Cancer 22:498","journal-title":"BMC Cancer"},{"key":"1191_CR94","doi-asserted-by":"publisher","first-page":"e81815","DOI":"10.1371\/journal.pone.0081815","volume":"8","author":"F-L Zhang","year":"2013","unstructured":"Zhang F-L et al (2013) Topoisomerase i inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS ONE 8:e81815","journal-title":"PLoS ONE"},{"key":"1191_CR95","doi-asserted-by":"publisher","first-page":"13405","DOI":"10.1021\/acs.analchem.0c02770","volume":"92","author":"Y Ma","year":"2020","unstructured":"Ma Y, Gao W, Ma S, Liu Y, Lin W (2020) Observation of the elevation of cholinesterase activity in brain glioma by a near-infrared emission chemsensor. Anal Chem 92:13405\u201313410","journal-title":"Anal Chem"},{"key":"1191_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/JEnvironPatholToxicolOncol.2021038740","volume":"40","author":"X Zhang","year":"2021","unstructured":"Zhang X et al (2021) T3 promotes glioma cell senescence and apoptosis via thra and thrb. J Environ Pathol Toxicol Oncol 40:1","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"1191_CR97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40824-023-00360-3","volume":"27","author":"X Li","year":"2023","unstructured":"Li X et al (2023) Albumin-binding photosensitizer capable of targeting glioma via the sparc pathway. Biomater Res 27:23","journal-title":"Biomater Res"},{"key":"1191_CR98","doi-asserted-by":"publisher","first-page":"718","DOI":"10.51620\/0869-2084-2021-66-12-718-721","volume":"66","author":"LM Obukhova","year":"2021","unstructured":"Obukhova LM et al (2021) Clinical significance of acetylcholinesterase activity in brain tumors. Klin Lab Diagn 66:718\u2013721","journal-title":"Klin Lab Diagn"},{"key":"1191_CR99","doi-asserted-by":"publisher","first-page":"149897","DOI":"10.1016\/j.bbrc.2024.149897","volume":"711","author":"S Tsuji","year":"2024","unstructured":"Tsuji S et al (2024) Linagliptin decreased the tumor progression on glioblastoma model. Biochem Biophys Res Commun 711:149897","journal-title":"Biochem Biophys Res Commun"},{"key":"1191_CR100","doi-asserted-by":"publisher","first-page":"e0169566","DOI":"10.1371\/journal.pone.0169566","volume":"12","author":"JE Jones","year":"2017","unstructured":"Jones JE et al (2017) Inhibition of acetyl-coa carboxylase 1 (acc1) and 2 (acc2) reduces proliferation and de novo lipogenesis of egfrviii human glioblastoma cells. PLoS ONE 12:e0169566","journal-title":"PLoS ONE"},{"key":"1191_CR101","doi-asserted-by":"publisher","first-page":"80358","DOI":"10.18632\/oncotarget.18673","volume":"8","author":"X Guo","year":"2017","unstructured":"Guo X et al (2017) Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via cxcr4\/akt\/emt pathway in human glioblastoma cells. Oncotarget 8:80358","journal-title":"Oncotarget"},{"key":"1191_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00979-y","volume":"13","author":"K Lei","year":"2020","unstructured":"Lei K et al (2020) Discovery of a dual inhibitor of nqo1 and gstp1 for treating glioblastoma. J Hematol Oncol 13:1\u201321","journal-title":"J Hematol Oncol"},{"key":"1191_CR103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.chembiol.2023.01.005","volume":"30","author":"TP Nguyen","year":"2023","unstructured":"Nguyen TP et al (2023) Selective and brain-penetrant lanosterol synthase inhibitors target glioma stem-like cells by inducing 24 (s), 25-epoxycholesterol production. Cell Chem Biol 30:214\u2013229","journal-title":"Cell Chem Biol"},{"key":"1191_CR104","doi-asserted-by":"publisher","first-page":"e10924","DOI":"10.15252\/emmm.201910924","volume":"12","author":"M Han","year":"2020","unstructured":"Han M et al (2020) Therapeutic implications of altered cholesterol homeostasis mediated by loss of cyp46a1 in human glioblastoma. EMBO Mol Med 12:e10924","journal-title":"EMBO Mol Med"},{"key":"1191_CR105","doi-asserted-by":"publisher","first-page":"172665","DOI":"10.1016\/j.ejphar.2019.172665","volume":"863","author":"M Zhao","year":"2019","unstructured":"Zhao M et al (2019) Dhfr\/tyms are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. Eur J Pharmacol 863:172665","journal-title":"Eur J Pharmacol"},{"key":"1191_CR106","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41598-021-04613-w","volume":"12","author":"J Kunikowska","year":"2022","unstructured":"Kunikowska J et al (2022) Expression of glutamate carboxypeptidase ii in the glial tumor recurrence evaluated in vivo using radionuclide imaging. Sci Rep 12:652","journal-title":"Sci Rep"},{"key":"1191_CR107","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3892\/ol.2015.3419","volume":"10","author":"B Ding","year":"2015","unstructured":"Ding B et al (2015) Expression of tyms in lymph node metastasis from low-grade glioma. Oncol Lett 10:1569\u20131574","journal-title":"Oncol Lett"},{"key":"1191_CR108","doi-asserted-by":"publisher","first-page":"146325","DOI":"10.1016\/j.gene.2022.146325","volume":"822","author":"H Liu","year":"2022","unstructured":"Liu H, Weng J (2022) A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (cdk2) in glioma. Gene 822:146325","journal-title":"Gene"},{"key":"1191_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-018-0598-5","volume":"11","author":"H Was","year":"2019","unstructured":"Was H et al (2019) Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. Clin Epigenet 11:1\u201313","journal-title":"Clin Epigenet"},{"key":"1191_CR110","doi-asserted-by":"publisher","first-page":"334","DOI":"10.21037\/atm-22-520","volume":"10","author":"F Lu","year":"2022","unstructured":"Lu F et al (2022) Hypomethylation-induced prognostic marker zinc finger dhhc-type palmitoyltransferase 12 contributes to glioblastoma progression. Ann Transl Med 10:334","journal-title":"Ann Transl Med"},{"key":"1191_CR111","doi-asserted-by":"publisher","first-page":"887294","DOI":"10.3389\/fonc.2022.887294","volume":"12","author":"H Jiang","year":"2022","unstructured":"Jiang H et al (2022) Rrm2 mediates the anti-tumor effect of the natural product pectolinarigenin on glioblastoma through promoting cdk1 protein degradation by increasing autophagic flux. Front Oncol 12:887294","journal-title":"Front Oncol"},{"key":"1191_CR112","doi-asserted-by":"publisher","first-page":"btaf604","DOI":"10.1093\/bioinformatics\/btaf604","volume":"41","author":"M Van Norden","year":"2025","unstructured":"Van Norden M, Mangione W, Falls Z, Samudrala R (2025) Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms. Bioinformatics 41:btaf604. https:\/\/doi.org\/10.1093\/bioinformatics\/btaf604","journal-title":"Bioinformatics"},{"key":"1191_CR113","doi-asserted-by":"publisher","first-page":"9318","DOI":"10.1038\/s41598-021-88485-0","volume":"11","author":"Y Yue","year":"2021","unstructured":"Yue Y et al (2021) Pre-diagnostic circulating concentrations of fat-soluble vitamins and risk of glioma in three cohort studies. Sci Rep 11:9318","journal-title":"Sci Rep"},{"key":"1191_CR114","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","volume":"21","author":"DD Bikle","year":"2014","unstructured":"Bikle DD (2014) Vitamin d metabolism, mechanism of action, and clinical applications. Chem Biol 21:319\u2013329","journal-title":"Chem Biol"},{"key":"1191_CR115","doi-asserted-by":"crossref","unstructured":"Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266\u2013281","DOI":"10.1056\/NEJMra070553"},{"key":"1191_CR116","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1038\/s41598-018-20844-w","volume":"8","author":"H Takahashi","year":"2018","unstructured":"Takahashi H et al (2018) Mendelian randomisation study of the relationship between vitamin d and risk of glioma. Sci Rep 8:2339","journal-title":"Sci Rep"},{"key":"1191_CR117","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1080\/01635581.2015.1073757","volume":"67","author":"V Zigmont","year":"2015","unstructured":"Zigmont V et al (2015) Association between prediagnostic serum 25-hydroxyvitamin d concentration and glioma. Nutr Cancer 67:1120\u20131130","journal-title":"Nutr Cancer"},{"key":"1191_CR118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-014-1416-3","volume":"118","author":"DG Salom\u00f3n","year":"2014","unstructured":"Salom\u00f3n DG et al (2014) Vitamin d receptor expression is associated with improved overall survival in human glioblastoma multiforme. J Neurooncol 118:49\u201360","journal-title":"J Neurooncol"},{"key":"1191_CR119","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.3390\/cancers15215249","volume":"15","author":"S Rehbein","year":"2023","unstructured":"Rehbein S et al (2023) Molecular determinants of calcitriol signaling and sensitivity in glioma stem-like cells. Cancers 15:5249","journal-title":"Cancers"},{"key":"1191_CR120","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3390\/nu14142873","volume":"14","author":"DE-R Osman","year":"2022","unstructured":"Osman DE-R et al (2022) Biomarkers regulated by lipid-soluble vitamins in glioblastoma. Nutrients 14:2873","journal-title":"Nutrients"},{"key":"1191_CR121","first-page":"837","volume":"12","author":"N Fauzee","year":"2011","unstructured":"Fauzee N, Dong Z, Wang YL (2011) Taxanes: promising anti-cancer drugs. Asian Pac J Cancer Prev 12:837\u201351","journal-title":"Asian Pac J Cancer Prev"},{"key":"1191_CR122","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790\u2013803","journal-title":"Nat Rev Drug Discov"},{"key":"1191_CR123","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","volume":"42","author":"AJ Ten Tije","year":"2003","unstructured":"Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665\u2013685","journal-title":"Clin Pharmacokinet"},{"key":"1191_CR124","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-013-2214-x","volume":"72","author":"D Semiond","year":"2013","unstructured":"Semiond D, Sidhu S, Bissery M-C, Vrignaud P (2013) Can taxanes provide benefit in patients with cns tumors and in pediatric patients with tumors? an update on the preclinical development of cabazitaxel. Cancer Chemother Pharmacol 72:515\u2013528","journal-title":"Cancer Chemother Pharmacol"},{"key":"1191_CR125","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cbin.10940","volume":"42","author":"A Neshasteh-Riz","year":"2018","unstructured":"Neshasteh-Riz A, Zeinizade E, Safa M, Mousavizadeh K (2018) Cabazitaxel inhibits proliferation and potentiates the radiation response of u87mg glioblastoma cells. Cell Biol Int 42:815\u2013822","journal-title":"Cell Biol Int"},{"key":"1191_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5342-9","volume":"19","author":"N Terada","year":"2019","unstructured":"Terada N et al (2019) The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in japanese patients. BMC Cancer 19:1\u20137","journal-title":"BMC Cancer"},{"key":"1191_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-021-01048-3","volume":"19","author":"J Li","year":"2021","unstructured":"Li J et al (2021) Active targeting of orthotopic glioma using biomimetic liposomes co-loaded elemene and cabazitaxel modified by transferritin. J Nanobiotechnol 19:1\u201319","journal-title":"J Nanobiotechnol"},{"key":"1191_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00894-020-04400-w","volume":"26","author":"L Zhu","year":"2020","unstructured":"Zhu L et al (2020) Binding modes of cabazitaxel with the different human $$\\beta $$-tubulin isotypes: Dft and md studies. J Mol Model 26:1\u201314","journal-title":"J Mol Model"},{"key":"1191_CR129","doi-asserted-by":"publisher","first-page":"759953","DOI":"10.3389\/fgene.2021.759953","volume":"12","author":"H Zhu","year":"2021","unstructured":"Zhu H et al (2021) Tuba1c is a prognostic marker in low-grade glioma and correlates with immune cell infiltration in the tumor microenvironment. Front Genet 12:759953","journal-title":"Front Genet"},{"key":"1191_CR130","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12272-012-0214-8","volume":"35","author":"H Gaoe","year":"2012","unstructured":"Gaoe H et al (2012) Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharmacal Res 35:333\u2013341","journal-title":"Arch Pharmacal Res"},{"key":"1191_CR131","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1166\/jbn.2015.2076","volume":"11","author":"H Gao","year":"2015","unstructured":"Gao H et al (2015) Preparation, characterization and anti-glioma effects of docetaxel-incorporated albumin-lipid nanoparticles. J Biomed Nanotechnol 11:2137\u20132147","journal-title":"J Biomed Nanotechnol"},{"key":"1191_CR132","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12935-022-02624-9","volume":"22","author":"P Dhyani","year":"2022","unstructured":"Dhyani P et al (2022) Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int 22:206","journal-title":"Cancer Cell Int"},{"key":"1191_CR133","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2174\/1385272825666210216123256","volume":"25","author":"S Mayer","year":"2021","unstructured":"Mayer S, Keglevich P, Keglevich A, Hazai L (2021) New anticancer vinca alkaloids in the last decade-a mini-review. Curr Org Chem 25:1224\u20131234","journal-title":"Curr Org Chem"},{"key":"1191_CR134","first-page":"177","volume":"2","author":"F Roussi","year":"2012","unstructured":"Roussi F, Gu\u00e9ritte F, Fahy J (2012) The vinca alkaloids. Anticancer Agents Nat Prod 2:177\u2013198","journal-title":"Anticancer Agents Nat Prod"},{"key":"1191_CR135","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-07-2219","volume":"14","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, Delord J-P, Campone M, Nguyen L (2008) Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 14:1625\u20131632","journal-title":"Clin Cancer Res"},{"key":"1191_CR136","doi-asserted-by":"publisher","first-page":"e65694","DOI":"10.1371\/journal.pone.0065694","volume":"8","author":"A Rovini","year":"2013","unstructured":"Rovini A et al (2013) Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in eb1 c-terminal detyrosinated\/tyrosinated status. PLoS ONE 8:e65694","journal-title":"PLoS ONE"},{"key":"1191_CR137","doi-asserted-by":"publisher","first-page":"24604","DOI":"10.18632\/oncotarget.8360","volume":"7","author":"X-T Li","year":"2016","unstructured":"Li X-T et al (2016) Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brain glioma along with eliminating glioma stem cells. Oncotarget 7:24604","journal-title":"Oncotarget"},{"key":"1191_CR138","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1166\/jbn.2015.2075","volume":"11","author":"J-F Shi","year":"2015","unstructured":"Shi J-F et al (2015) A combination of targeted sunitinib liposomes and targeted vinorelbine liposomes for treating invasive breast cancer. J Biomed Nanotechnol 11:1568\u20131582","journal-title":"J Biomed Nanotechnol"},{"key":"1191_CR139","first-page":"215","volume":"4","author":"E Bouffet","year":"2002","unstructured":"Bouffet E et al (2002) Weekly vinblastine for recurrent\/progressive low grade gliomas. Neuro Oncol 4:215","journal-title":"Neuro Oncol"},{"key":"1191_CR140","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/cncr.21091","volume":"103","author":"L Lafay-Cousin","year":"2005","unstructured":"Lafay-Cousin L et al (2005) Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103:2636\u20132642","journal-title":"Cancer"},{"key":"1191_CR141","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/BCJ20160583","volume":"475","author":"JL Delgado","year":"2018","unstructured":"Delgado JL, Hsieh C-M, Chan N-L, Hiasa H (2018) Topoisomerases as anticancer targets. Biochem J 475:373\u2013398","journal-title":"Biochem J"},{"key":"1191_CR142","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1046\/j.1365-2710.2001.00368.x","volume":"26","author":"Z Topcu","year":"2001","unstructured":"Topcu Z (2001) Dna topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26:405\u2013416","journal-title":"J Clin Pharm Ther"},{"key":"1191_CR143","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00686188","volume":"36","author":"PJ Houghton","year":"1995","unstructured":"Houghton PJ et al (1995) Efficacy of topoisomerase i inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393\u2013403","journal-title":"Cancer Chemother Pharmacol"},{"key":"1191_CR144","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF00685936","volume":"34","author":"HS Friedman","year":"1994","unstructured":"Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34:171\u2013174","journal-title":"Cancer Chemother Pharmacol"},{"key":"1191_CR145","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1158\/0008-5472.CAN-04-2116","volume":"64","author":"A Rapisarda","year":"2004","unstructured":"Rapisarda A et al (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1$$\\alpha $$ protein accumulation, angiogenesis, and tumor growth by topotecan in u251-hre glioblastoma xenografts. Can Res 64:6845\u20136848","journal-title":"Can Res"},{"key":"1191_CR146","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11060-012-1023-0","volume":"111","author":"J Hu","year":"2013","unstructured":"Hu J et al (2013) A phase ii trial of oral gimatecan for recurrent glioblastoma. J Neurooncol 111:347\u2013353","journal-title":"J Neurooncol"},{"key":"1191_CR147","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516\u20131516","journal-title":"J Clin Oncol"},{"key":"1191_CR148","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1014532202188","volume":"56","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC (2002) Salvage chemotherapy with cpt-11 for recurrent glioblastoma multiforme. J Neurooncol 56:183\u2013188","journal-title":"J Neurooncol"},{"key":"1191_CR149","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/01.cad.0000131687.08175.14","volume":"15","author":"G Pratesi","year":"2004","unstructured":"Pratesi G, Beretta GL, Zunino F (2004) Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15:545\u2013552","journal-title":"Anticancer Drugs"},{"key":"1191_CR150","unstructured":"Folic acid (db00158) \u2013 drugbank online (2026) https:\/\/go.drugbank.com\/drugs\/DB00158. Accessed 09 Jan 2026"},{"key":"1191_CR151","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1017\/S1368980021000562","volume":"24","author":"JC van der Pols","year":"2021","unstructured":"van der Pols JC, Baade P, Spencer LB (2021) Colorectal cancer incidence in Australia before and after mandatory fortification of bread flour with folic acid. Public Health Nutr 24:1989\u20131992","journal-title":"Public Health Nutr"},{"key":"1191_CR152","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1651-2227.2012.02781.x","volume":"101","author":"M J\u00e4gerstad","year":"2012","unstructured":"J\u00e4gerstad M (2012) Folic acid fortification prevents neural tube defects and may also reduce cancer risks. Acta Paediatr 101:1007\u20131012","journal-title":"Acta Paediatr"},{"key":"1191_CR153","doi-asserted-by":"crossref","unstructured":"Rudd M (2017) Folate: Friend or Foe? An investigation into the opposing roles of folate in glioma. Ph.D. thesis, University of Central Lancashire","DOI":"10.1093\/neuonc\/nox238.074"},{"key":"1191_CR154","first-page":"1","volume":"22","author":"D Li","year":"2021","unstructured":"Li D et al (2021) Lidocaine liposome modified with folic acid suppresses the proliferation and motility of glioma cells via targeting the pi3k\/akt pathway. Exp Ther Med 22:1\u201310","journal-title":"Exp Ther Med"},{"key":"1191_CR155","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fonc.2018.00419","volume":"8","author":"KK Jain","year":"2018","unstructured":"Jain KK (2018) A critical overview of targeted therapies for glioblastoma. Front Oncol 8:419","journal-title":"Front Oncol"},{"key":"1191_CR156","doi-asserted-by":"publisher","first-page":"946752","DOI":"10.3389\/fphar.2022.946752","volume":"13","author":"A Zhao","year":"2022","unstructured":"Zhao A et al (2022) A review of neuroprotective effects and mechanisms of ginsenosides from panax ginseng in treating ischemic stroke. Front Pharmacol 13:946752","journal-title":"Front Pharmacol"},{"key":"1191_CR157","first-page":"8858006","volume":"2021","author":"H Hong","year":"2021","unstructured":"Hong H, Baatar D, Hwang SG (2021) Anticancer activities of ginsenosides, the main active components of ginseng. Evidence-Based Complementary Altern Med 2021:8858006","journal-title":"Evidence-Based Complementary Altern Med"},{"key":"1191_CR158","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/ptr.7395","volume":"36","author":"J Lu","year":"2022","unstructured":"Lu J et al (2022) Ginsenosides in central nervous system diseases: pharmacological actions, mechanisms, and therapeutics. Phytother Res 36:1523\u20131544","journal-title":"Phytother Res"},{"key":"1191_CR159","first-page":"2758","volume":"53","author":"J-Y Cai","year":"2018","unstructured":"Cai J-Y et al (2018) Histone deacetylase hdac4 promotes the proliferation and invasion of glioma cells. Int J Oncol 53:2758\u20132768","journal-title":"Int J Oncol"},{"key":"1191_CR160","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/DDDT.S160020","volume":"12","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the erk\/nrf2 signaling pathway. Drug Des Dev Ther 12:721\u2013733","journal-title":"Drug Des Dev Ther"},{"key":"1191_CR161","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0306-4522(89)90269-8","volume":"30","author":"A Szallasi","year":"1989","unstructured":"Szallasi A, Blumberg P (1989) Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 30:515\u2013520","journal-title":"Neuroscience"},{"key":"1191_CR162","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.apsb.2021.11.001","volume":"12","author":"T Zhong","year":"2022","unstructured":"Zhong T et al (2022) The regulatory and modulatory roles of trp family channels in malignant tumors and relevant therapeutic strategies. Acta Pharm Sin B 12:1761\u20131780","journal-title":"Acta Pharm Sin B"},{"key":"1191_CR163","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11010-013-1711-x","volume":"381","author":"L Lu","year":"2013","unstructured":"Lu L et al (2013) Cryptotanshinone inhibits human glioma cell proliferation by suppressing stat3 signaling. Mol Cell Biochem 381:273\u2013282","journal-title":"Mol Cell Biochem"},{"key":"1191_CR164","unstructured":"Brivaracetam (db05541) \u2013 drugbank online (2026) https:\/\/go.drugbank.com\/drugs\/DB05541. Accessed 09 Jan 2026"},{"key":"1191_CR165","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3389\/fneur.2020.00813","volume":"11","author":"M Maschio","year":"2020","unstructured":"Maschio M et al (2020) Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study. Front Neurol 11:813","journal-title":"Front Neurol"},{"key":"1191_CR166","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2274968","author":"Ritu","year":"2023","unstructured":"Ritu A, Chandra P, Das A (2023) Cholinergic side effect-free anticancer drugs: paving the way for safer and more effective cancer treatment. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2023.2274968","journal-title":"J Biomol Struct Dyn"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13321-026-01191-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-026-01191-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-026-01191-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:03:28Z","timestamp":1779149008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13321-026-01191-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1186\/s13321-026-01191-9","relation":{},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}